TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively cor...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2020-01, Vol.9 (1), p.1843247-1843247
Hauptverfasser:	Maas, Ralph Ja, Hoogstad-van Evert, Janneke S, Van der Meer, Jolien Mr, Mekers, Vera, Rezaeifard, Somayeh, Korman, Alan J, de Jonge, Paul Kjd, Cany, Jeannette, Woestenenk, Rob, Schaap, Nicolaas Pm, Massuger, Leon F, Jansen, Joop H, Hobo, Willemijn, Dolstra, Harry
Format:	Artikel
Sprache:	eng
Schlagworte:	CD96 checkpoint blockade DNAM-1 NK cells Original Research Ovarian cancer TIGIT
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!